Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Intravesical Natural Baobab Oil in the Management of BCG-induced Lower Urinary Tract Symptoms (Baobab)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01939756
Recruitment Status : Completed
First Posted : September 11, 2013
Last Update Posted : September 11, 2013
Sponsor:
Collaborator:
University of Bari
Information provided by (Responsible Party):
Savino M. Di Stasi, University of Rome Tor Vergata

Brief Summary:
Baobab oil is often used in traditional medicine as antipyretic, antioxidant, anti-inflammatory, analgesic and antimicrobial. It also regenerates the epithelial tissue in a short time improving tone and elasticity. We want to evaluate the effects of intravesical Baobab oil in patients with BCG-induced lower urinary tract symptoms.

Condition or disease Intervention/treatment Phase
Superficial Bladder Cancer Lower Urinary Tract Symptoms Device: Intravesical baobab oil Phase 1 Phase 2

Detailed Description:

After complete transurethral resection of primary high risk non-muscle invasive bladder tumors (stage pTa, pT1, carcinoma in situ and high grade urothelial carcinoma), patients on induction course of intravesical BCG with lower urinary tract symptoms unresponsive to standard therapies are enrolled. The patients supply written informed consent to a document describing the investigational nature of the protocol.

Induction treatment consists of an initial 6 intravesical BCG treatments at weekly interval commencing approximately 3 weeks after transurethral resection procedures. The BCG instillation consisted of 81 mg wet weight (10•2±9•0 x 108 colony-forming units) BCG Connaught substrain. Lyophilised (ie, freeze-dried) BCG is suspended in 50 mL bacteriostatic-free solution of 0•9% sodium chloride. After draining of the bladder, the suspension is infused intravesically through a Foley catheter. The solution is retained in the bladder for 120 min, followed by emptying of the bladder and removal of the catheter.

During BCG treatment patients with persistent lower urinary tract symptoms unresponsive to standard therapies (anticholinergics, alpha-blockers, antibiotics, analgesics and anti-inflammatory drugs) are treated with an intravesical instillation of 50 ml sterile Baobab natural oil (Baotrophic, Physion Srl, Mirandola, Italy). After draining of the bladder, the suspension is infused intravesically through a Foley catheter. The solution is retained in the bladder for 60 min, followed by emptying of the bladder and removal of the catheter.

Lower urinary tract symptoms are self-recorded by the patients before and after each baobab oil instillation and classified by the investigator according to a classification grid considering account duration and intensity. The classification of symptoms is class 0= none, class I = mild, class II = moderate, and class III = severe, according to severity. Local adverse events are cystitis, nocturia, pollakiuria, micturition urgency, micturition burning, stress urinary incontinence, dysuria, hematuria, pelvic pain, and perineal pain. The outcome measures are analyzed before and every day for one week after treatment. All patients are assessed for safety.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Intravesical Natural Baobab Oil in the Management of BCG-induced Lower Urinary Tract Symptoms: a Phase I-II Study
Study Start Date : January 2012
Actual Primary Completion Date : June 2013
Actual Study Completion Date : June 2013

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Intravesical baobab oil
Intravesical instillation of 50 ml sterile Baobab natural oil. After draining of the bladder, the suspension is infused intravesically through a Foley catheter. The solution is retained in the bladder for 60 min, followed by emptying of the bladder and removal of the catheter.
Device: Intravesical baobab oil
Intravesical baobab oil
Other Name: Baotrophic, Physion Srl, Mirandola, Italy




Primary Outcome Measures :
  1. Quantitative symptom score questionnaire [ Time Frame: 36 months ]
    A quantitative symptom score questionnaire is completed by the patients before treatment to establish baseline symptoms and daily during the following 7 days after treatment. The questionnaire is designed to evaluate 10 lower urinary tract symptoms (cystitis, nocturia, pollakiuria, micturition urgency, micturition burning, stress urinary incontinence, dysuria, hematuria, pelvic pain, and perineal pain. Most symptoms are scored on a 0 to 3-point scale, corresponding to none/mild/moderate/severe.


Secondary Outcome Measures :
  1. Baobab oil toxicity [ Time Frame: 36 months ]
    All patients are assessed for safety or allergy to intravesical baobab oil



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 18 years or older
  • Complete transurethral resection of primary histologically proven high risk urothelial non-muscle invasive bladder tumors: high grade (G3,) stage pTa, pT1, and carcinoma in situ (pTis
  • Intravesical BCG treatment
  • Adequate bone marrow reserve (ie, white-blood-cell count ≥4000 x106 cells/L and platelet count

    ≥120 x 109/L

  • Normal renal function (function (ie, serum creatinine ≤123•76 µmol/L)
  • normal liver function ((ie, serum glutamic-oxaloacetic transaminase ≤42 U/L, serum glutamic-pyruvic transaminase ≤48 U/L, and total bilirubin ≤22•23 µmol/L)
  • Karnofsky performance score of 50 to 100

Exclusion Criteria:

  • Previous intravesical treatment with chemotherapeutic and immunotherapeutic drugs
  • Previous or concomitant urothelial carcinoma of the upper urinary tract and urethra, or both
  • Previous muscle-invasive (ie, stage T2 or higher) urothelia carcinoma of the bladder
  • Known allergy to baobab oil
  • Bladder capacity less than 200 mL
  • Untreated urinary-tract infection
  • Severe systemic infection (ie, sepsis)
  • Urethral strictures that would prevent endoscopic procedures and catheterisation
  • Disease of upper urinary tract (eg, vesicoureteral reflux or urinary-tract stones) that would make multiple transurethral procedures at risk
  • Previous radiotherapy to the pelvis;
  • Other concurrent chemotherapy;
  • Treatment with radiotherapy-response or biological-response modifiers;
  • Other malignant diseases within 5 years of trial registration (except for basal-cell carcinoma);
  • Pregnancy or nursing;
  • Psychological, familial, sociological, or geographical factors that would preclude study participation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01939756


Locations
Layout table for location information
Italy
Savino M. Di Stasi
Rome, Italy, 00133
Tor Vergata University
Rome, Italy, 00133
Sponsors and Collaborators
Savino M. Di Stasi
University of Bari
Investigators
Layout table for investigator information
Study Chair: Savino M Di Stasi, MD, PhD Tor Vergata University, Rome, Italy

Layout table for additonal information
Responsible Party: Savino M. Di Stasi, Associate Professor of Urology, MD, PhD, University of Rome Tor Vergata
ClinicalTrials.gov Identifier: NCT01939756     History of Changes
Other Study ID Numbers: UTV-101-2012
First Posted: September 11, 2013    Key Record Dates
Last Update Posted: September 11, 2013
Last Verified: September 2013

Keywords provided by Savino M. Di Stasi, University of Rome Tor Vergata:
High risk non-muscle invasive urothelial bladder cancer
Intravesical BCG
Local toxicity
Natural baobab oil

Additional relevant MeSH terms:
Layout table for MeSH terms
Urinary Bladder Neoplasms
Lower Urinary Tract Symptoms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Urinary Bladder Diseases
Urologic Diseases
Urological Manifestations
Signs and Symptoms